-
Article
Open AccessA comprehensive pan-cancer analysis of prognostic value and potential clinical implications of FTH1 in cancer immunotherapy
Numerous studies have highlighted the crucial value of the heavy chain of ferritin (FTH1) as a key regulator of iron metabolism and a suppressor of ferroptosis, intimately tied to the tumor immune microenviron...
-
Article
Open AccessCostimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer
Owing to the paucity of specimens, progress in identifying prognostic and therapeutic biomarkers for small cell lung cancer (SCLC) has been stagnant for decades. Considering that the costimulatory molecules ar...
-
Article
Open AccessSingle-cell analysis reveals the potential mechanisms of pyrotinib resistance in non-small cell lung cancer
-
Article
Open AccessA novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma
Except for B7-CD28 family members, more novel immune checkpoints are being discovered. They are closely associated with tumor immune microenvironment and regulate the function of many immune cells. Various can...
-
Article
Open AccessNivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC
-
Article
Open AccessThe potential role of N7-methylguanosine (m7G) in cancer
N7-methylguanosine (m7G), one of the most prevalent RNA modifications, has recently attracted significant attention. The m7G modification actively participates in biological and pathological functions by affecti....
-
Article
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China
The optimal mode of neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC) has not been well characterized. Our study compared neoadjuvant chemotherapy (NCT) with neoadjuvant chemoradiotherapy (NC...
-
Article
Open AccessAn immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer
Patients with small-cell lung cancer (SCLC) are burdened by limited treatment options and the disease’s dismal prognosis. Long non-coding RNAs (lncRNAs) are essential regulators of genetic alteration and are a...
-
Article
Open Accessm6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer
Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy—with or without immune checkpoint inhibitors (anti-PDs)—is the current first-line therapy for SCLC...
-
Article
Open Accessm6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
Small-cell lung cancer (SCLC) is a devastating subtype of lung cancer with few therapeutic options. Despite the advent of immunotherapy, platinum-based chemotherapy is still the irreplaceable first-line therap...
-
Article
Open AccessThe landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
-
Article
Open AccessAn individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma
No clinically available biomarkers can predict pathological complete response (pCR) for esophageal squamous cell carcinomas (ESCCs) with neoadjuvant chemoradiotherapy (nCRT). Considering that antitumor immunit...